Fundador Adajar, MD
Cardiovascular Disease · Roswell, NMNPI 1013919232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 492 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,102 and has fallen 72.5% since, to $577 in 2025.
Across 492 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boston Scientific$1K
- Novartis$1K
- Amgen$858
- Pfizer$672
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$620
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,282100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,031 |
| Boston Scientific | 60 | $1,012 |
| Novartis | 70 | $1,005 |
| Amgen | 50 | $858 |
| Pfizer | 53 | $672 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 43 | $620 |
| Amarin Pharma, Inc. | 34 | $590 |
| Boehringer Ingelheim | 30 | $551 |
| Johnson & Johnson | 30 | $462 |
| Abbott | 11 | $359 |
| Axonics, Inc. | 7 | $231 |
| E.r. Squibb & Sons, L.L.C. | 11 | $195 |
| Philips North America LLC | 7 | $195 |
| Merck | 5 | $111 |
| Bayer | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Impulse Dynamics (USA) Inc. | 2 | $41 |
| Itamar Medical Inc | 2 | $40 |
| Olympus America Inc. | 1 | $40 |
| Novo Nordisk | 2 | $30 |
| Shockwave Medical, Inc | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Elutia, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Medtronic | 1 | $20 |
| Aegerion Pharmaceuticals, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $14 |
How this compares
$8,302 in reported general payments places this provider in the 80th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 667 | $684,855 |
| XareltoRivaroxaban | 483 | $555,740 |
| EntrestoSacubitril/Valsartan | 313 | $345,651 |
| Repatha SureclickEvolocumab | 245 | $210,277 |
| OzempicSemaglutide | 140 | $197,466 |
| FarxigaDapagliflozin Propanediol | 138 | $112,171 |
| BrilintaTicagrelor | 88 | $76,171 |
| MounjaroTirzepatide | 66 | $66,909 |
| JardianceEmpagliflozin | 64 | $65,434 |
| VascepaIcosapent Ethyl | 41 | $36,271 |
| WegovySemaglutide | 18 | $24,458 |
| Atorvastatin Calcium | 1,531 | $20,016 |
| Potassium Chloride | 824 | $16,383 |
| Metoprolol Succinate | 993 | $15,604 |
| Ranolazine ErRanolazine | 88 | $11,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $672 | $684,855667 claims |
| Johnson & JohnsonXarelto | $462 | $555,740483 claims |
| NovartisEntresto | $1,005 | $345,651313 claims |
| Novo NordiskOzempic, Wegovy | $30 | $221,924158 claims |
| AstraZenecaFarxiga, Brilinta | $1,031 | $188,343226 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $551 | $70,93676 claims |
| Lilly USA, LLCMounjaro | $21 | $66,90966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Roswell
- Hamid FerozeRoswell$4K
- Eric CohenRoswell$2K
- Abinash AchrekarAlbuquerque$88K
- Suresh NeelagaruChama$46K
- Adam BanksAlbuquerque$38K
- Jose Rodriguez ArciniegaLas Cruces$24K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- William RobinsonFarmington$14K
- Muhammad AnwarLas Cruces$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.